EAACI Congress 2023
BackBiologicals in asthma – from clinical trials to real life
Friday 09 Jun, 13:15 PM -
14:45 PM CEST
Hall Y 03+04
ORAL Session
13:15
Efficacy of Dupilumab in Patients With Asthma Stratified by a Minimally Important Fractional Exhaled Nitric Oxide Reduction at Week 2 of Treatment
13:27
Tezepelumab efficacy in dupilumab-eligible patients: a pooled analysis from the PATHWAY and NAVIGATOR studies
13:39
Dupilumab is effective in children (6–11 years) with moderate-to-severe asthma and high eosinophils at baseline
13:51
The impact of mepolizumab self-administration on real-world outcomes in patients with severe asthma: post hoc analysis of REALITI-A at 2 years
14:03
Efficacy of tezepelumab in patients with perennial allergy grouped by specific immunoglobulin E thresholds and by age
14:15
Evaluation of asthma control and quality of life in elderly patients under biological monoclonal antibody
14:27
Long-Term Safety of Dupilumab in Patients with Moderate-to-Severe Asthma Who Completed the LIBERTY ASTHMA TRAVERSE Continuation Study
